What is the Historic and Current Scenario of the Post-Traumatic Stress Disorder Therapeutics Market?
The post-traumatic stress disorder therapeutics market has seen considerable growth due to a variety of factors.
• In recent years, there has been consistent growth in the market size of therapeutics for post-traumatic stress disorder (PTSD). This market is predicted to expand from $1.14 billion in 2024 to $1.19 billion in 2025, experiencing a compound annual growth rate (CAGR) of 4.9%. Several factors from the historic period have contributed to this growth, including increased awareness about PTSD, a rise in trauma incidence rates, various government campaigns, progress in diagnostic methods, the diminishing stigma related to mental health, the introduction of psychological support programs, and a concentrated focus on veterans' healthcare.
How Does the Forecast Look for the Post-Traumatic Stress Disorder Therapeutics Market By 2029?
The Post-Traumatic Stress Disorder Therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size for therapeutics for post-traumatic stress disorder is anticipated to undergo steady expansion. The predicted growth has it reaching $1.38 billion by 2029, with a compound annual growth rate (CAGR) of 3.8%.
Factors contributing to the growth expected during this forecast period include enhanced availability of mental health services, mental health policies implemented by the government, research in biology and neurology, instances of PTSD in civilian populations, and strategies for crisis response. Key trends projected during this forecast period encompass the incorporation of digital therapeutics, strides in pharmacological treatment approaches, the use of neurostimulation and brain stimulation techniques, therapy aided by psychedelics, and joint research efforts.
What Are The Leading Drivers Of Growth In The Post Traumatic Stress Disorder Therapeutics Market?
The global increase in cases of post-traumatic stress disorder (PTSD) is anticipated to stimulate the expansion of the market for PTSD therapeutics. PTSD is a condition that emerges in individuals who have endured terrifying, surprising or threatening events. Treatments for PTSD, such as psychotherapy and medication, can assist individuals in regaining control over their lives. For example, the UK's Ministry of Defence (MoD) Department of Community Mental Health (DCMH), a company which provides mental health services to current service members and reservists, reported in March 2024 that the number of military personnel undergoing initial PTSD evaluations by mental health specialists escalated from 266 cases in 2022 to 320 cases in 2023, as stated on a UK-based defense industry news website. This significant increase in recorded PTSD cases is subsequently fueling the growth of the post-traumatic stress disorder therapeutics market.
How Are The Segments Defined Within The Global Post Traumatic Stress Disorder Therapeutics Market?
The post-traumatic stress disorder therapeutics market covered in this report is segmented –
1) By Drug Class: Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes
2) By Age Group: Pediatric, Geriatric, Adult
3) By End User: Mental Health Center, Hospitals, Outpatient Clinics, Other End Users
Subsegments:
1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
2) By Anti-Anxiety: Benzodiazepines, Buspirone
3) By Antihypertensive: Prazosin, Clonidine
4) By Monoamine Oxidase Inhibitors (MAOs): Traditional MAOIs, Reversible MAOIs
5) By Antipsychotics (Second Generation Antipsychotics - SGOs): Risperidone, Quetiapine
6) By Beta-Blockers: Propranolol, Atenolol
7) By Other Classes: Mood Stabilizers, Adjunctive Therapies
Pre-Book The Post Traumatic Stress Disorder Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Post Traumatic Stress Disorder Therapeutics Market?
Important collaborations, financial support, and investments have surfaced as a significant pattern in the post-traumatic stress disorder therapeutics industry. Predominant firms in the marketplace have been cultivating strategic collaborations and investments to fortify their market position. For example, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky from Monash University - part of an interdisciplinary research group - were granted over $1.9 million in January 2022. Their research focuses on the effectiveness of MDMA-assisted psychological intervention for the treatment of alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). This exploration is one of seven clinical trials initiated by the Medical Research Future Fund (MRFF) under the auspices of the Federal government this month, aiming to examine the potential of innovative combination drugs to address severe mental illnesses.
Who Are the Key Players In The Post Traumatic Stress Disorder Therapeutics Market?
Major companies operating in the post-traumatic stress disorder therapeutics market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• Bionomics Limited
• Otsuka Pharmaceutical Co Ltd.
• Eli Lilly and Company
• AstraZeneca plc
• Tonix Pharmaceuticals Holding Corp.
• Freespira Inc.
• MicroTransponder Inc.
• Compass Pathways plc
• Boehringer Ingelheim International GmbH
• Halucenex Life Sciences Inc.
• Bionorica SE
• MAPS Europe BV
• Hoffmann-La Roche Ltd.
• Praxis Precision Medicines Inc.
• H Lundbeck A/S
• Johnson & Johnson
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Jazz Pharmaceuticals plc
What Is The Most Dominant Region In The Post Traumatic Stress Disorder Therapeutics Market?
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
